Have a personal or library account? Click to login
Mucopolysaccharidosis type I - Clinical and genetic characteristics of Romanian patients Cover

Mucopolysaccharidosis type I - Clinical and genetic characteristics of Romanian patients

Open Access
|Jul 2020

References

  1. 1. The mucopolysaccharidoses. The metabolic and molecular bases of inherited disease; [Internet]. 2001.
  2. 2. D’Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. 2012;171(6):911-9.10.1007/s00431-011-1644-x
  3. 3. Scott HS, Guo X-H, Hopwood JJ, Morris CP. Structure and sequence of the human α-L-iduronidase gene. Genomics. 1992;13(4):1311-3.10.1016/0888-7543(92)90053-U
  4. 4. Taylor J, Gibson G, Brooks D, Hopwood J. α-l-Iduronidase in normal and mucopolysaccharidosis-type-I human skin fibroblasts. Bioch J. 1991;274 (Pt 1):263-8.10.1042/bj2740263
  5. 5. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hop-wood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat. 1995;6(4):288-302.10.1002/humu.1380060403
  6. 6. Brooks D. The immunochemical analysis of enzyme from mucopolysaccharidoses patients. JIMD. 1993;16(1):3-15.10.1007/BF00711309
  7. 7. Scott HS, Litjens T, Nelson PV, Brooks DA, Hopwood JJ, Morris CP. α-L-Iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum Mutat. 1992;1(4):333-9.10.1002/humu.1380010412
  8. 8. Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, et al. IDUA mutational profiling of a cohort of 102 European patients with mucopolysaccharidosis type I: identification and characterization of 35 novel α-L-iduronidase (IDUA) alleles. Hum Mutat. 2011;32(6):E2189-210.10.1002/humu.21479
  9. 9. Clarke LA, Nelson PV, Warrington CL, Morris CP, Hopwood JJ, Scott HS. Mutation analysis of 19 North American mucopolysaccharidosis type I patients: identification of two additional frequent mutations. Hum Mutat. 1994;3(3):275-82.10.1002/humu.1380030316
  10. 10. Jurca C, Bembea M, Pallag A, Muresan M, Szilagyi A, Balmos A, et al. Pharmacotherapeutical considerations in the treatment and management of neonatal hyperammonaemia. Farmacia. 2018;66(2):216-22.
  11. 11. Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D. Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J. 2002;3(1):17-20.10.1038/sj.thj.6200152
  12. 12. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112-9.10.1016/S0002-9343(02)01150-6
  13. 13. Wang D, Shukla C, Liu X, Schoeb TR, Clarke LA, Bed-well DM, et al. Characterization of an MPS IH knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Mol Genet Metab. 2010;99(1):62-71.10.1016/j.ymgme.2009.08.002279504019751987
  14. 14. Taghikhani M, Khatami S, Abdi M, Hakhamaneshi MS, Alaei MR, Zamanfar.D J. Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I. Clin Lab Anal. 2019;00:e2296310.1002/jcla.22963680531931386236
  15. 15. Zahoor MY, Cheema HA, Ijaz S, Anjum MN, Ramzan K, Bhinder MA. Mapping of IDUA gene variants in Pakistani patients with mucopolysaccharidosis type 1. J Pediatr Endocrinol Metab. 2019;32(11):1221-1227.10.1515/jpem-2019-018831473686
  16. 16. Clarke LA, Giugliani R, Guffon N, Jones SA, Keenan HA, Munoz-Rojas MV et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry. Clin Genet. 2019;96(4):281-289.10.1111/cge.13583685215131194252
  17. 17. Zanetti A, D’Avanzo F, Rigon L, Rampazzo A, Concolino D, Barone R, et al. Molecular diagnosis of patients affected by mucopolysaccharidosis: a multicenter study. Eur J Pediatr. 2019;178(5):739-753.10.1007/s00431-019-03341-8645979130809705
  18. 18. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet. 2001;109(5):503-11.10.1007/s00439010060611735025
  19. 19. Pollard LM, Jones JR, Wood TC. Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. JIMD. 2013;36(2):179-87.10.1007/s10545-012-9533-722976768
  20. 20. Bunge S, Kleijer WJ, Steglich C, Beck M, Zuther C, Morris CP, et al. Mucopolysaccharidosis type I: identification of 8 novel mutations and determination of the frequency of the two common α-L-iduronidase mutations (W402X and Q70X) among European patients. Hum Mol Genet. 1994;3(6):861-6.10.1093/hmg/3.6.8617951228
  21. 21. Uttarilli A, Ranganath P, Matta D, Md Nurul Jain J, Prasad K, Babu AS, et al. Identification and characterization of 20 novel pathogenic variants in 60 unrelated Indian patients with mucopolysaccharidoses type I and type II. Clin Genet. 2016;90(6):496-508.10.1111/cge.1279527146977
  22. 22. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literature. Genet Med. 2003;5(4):286-94.10.1097/01.GIM.0000078027.83236.4912865757
  23. 23. Yogalingam G, Guo XH, Muller V, Brooks DA, Clements P, Kakkis E, et al. Identification and molecular characterization of α-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat. 2004;24(3):199-207.10.1002/humu.20081
  24. 24. Gatti R, DiNatale P, Villani G, Filocamo M, Muller V, Guo X-H, et al. Mutations among Italian mucopolysaccharidosis type I patients. Journal of inherited metabolic disease. 1997;20(6):803-6.10.1023/A:1005323918923
  25. 25. Gort L, Chabás A, Coll MJ. Analysis of five mutations in 20 mucopolysaccharidosis type I patients: high prevalence of the W402X mutation. Hum Mutat. 1998;11(4):332-3.10.1002/(SICI)1098-1004(1998)11:4<332::AID-HUMU16>3.0.CO;2-P
  26. 26. Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L, et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2003;78(1):37-43.10.1016/S1096-7192(02)00200-7
  27. 27. Li P, Wood T, Thompson JN. Diversity of mutations and distribution of single nucleotide polymorphic alleles in the human α-l-iduronidase (IDUA) gene. Genet Med. 2002;4(6):420.10.1097/00125817-200211000-00004
DOI: https://doi.org/10.2478/rrlm-2020-0030 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Language: English
Page range: 279 - 286
Submitted on: Apr 12, 2020
Accepted on: Jul 7, 2020
Published on: Jul 27, 2020
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:

© 2020 Camelia Alkhzouz, Cecilia Lazea, Diana Miclea, Carmen Asavoaie, Ioana Nascu, Tudor Pop, Paula Grigorescu-Sido, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution 4.0 License.